ECOR - NASDAQ
electroCore, Inc.
$9.75
-1.1%electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld device for regular or intermittent use over many years. The company was incorporated in 2005 and is headquartered in Rockaway, New Jersey.
At a Glance
Live SnapshotelectroCore, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
electroCore, Inc. Income Statement
ECOR • NASDAQ
| electroCore, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||
32M | 25.2M | 16M | 8.6M | 5.5M | 3.5M | 2.4M | 993K | 811.5K | 254.1K | |
GROSS PROFIT | ||||||||||
(4.2M) | (3.8M) | (2.8M) | (1.6M) | (1.4M) | (1.7M) | (1.2M) | (578.7K) | (518.5K) | (123.7K) | |
27.8M | 21.4M | 13.2M | 7M | 4.1M | 1.8M | 1.2M | 414.2K | 292.9K | 130.4K | |
OPERATING INCOME | ||||||||||
(40.9M) | (33.6M) | (32M) | (29.9M) | (24.1M) | (26.5M) | (47.3M) | (55M) | (25.9M) | (15.1M) | |
(38.2M) | (31.2M) | (26.7M) | (24.3M) | (21.6M) | (21.8M) | (35.4M) | (42.5M) | (18.1M) | (7.2M) | |
(2.7M) | (2.4M) | (5.3M) | (5.5M) | (2.5M) | (4.2M) | (9.9M) | (12.5M) | (7.8M) | (8M) | |
-13.2M | -12.2M | -18.8M | -22.9M | -20M | -24.7M | -46.1M | -54.6M | -25.6M | -15M | |
PRE-TAX INCOME | ||||||||||
(590K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (7.1M) | (771.2K) | |
-292K | 572K | 433K | 287K | 11K | 84.3K | 970.6K | 1M | -7M | -771.2K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (464.6K) | (2M) | -344.9K | -4.9K | (0.0) | |
-810K | 183K | -215K | 281K | 2M | 66.6K | 958.3K | -1.2M | -10.4M | -771.2K | |
-14M | -12M | -19M | -22.6M | -18.1M | -24.7M | -45.1M | -55.8M | -36M | -15.8M | |
NET INCOME | ||||||||||
(3K) | -93K | -186K | -431K | -851K | -1.2M | (17.7K) | (2.4K) | (0.0) | -44.1K | |
-14M | -11.9M | -18.8M | -22.2M | -17.2M | -23.5M | -45.1M | -55.8M | -35.8M | -15.7M |
SEC Filings
ECOR - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 19, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 20, 2026 | January 20, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 05, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 05, 2025 | November 05, 2025 | 2025 | |
S-3 S-3 N/A | October 03, 2025 | October 03, 2025 | ||
8-K 8-K 2025 N/A | October 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | September 03, 2025 | September 02, 2025 | 2025 |
Related Guides
Continue your ECOR research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.